NanoViricides Advances Antiviral NV-387 in Phase II Trials

NanoViricides, Inc. has filed its quarterly report, highlighting the advancement of its broad-spectrum antiviral, NV-387. The drug is being positioned for a Phase II clinical trial aimed at treating MPox infections in the Democratic Republic of Congo. With no existing drug for MPox, a disease with a higher fatality rate than COVID, NV-387 represents a significant development. The trial was granted approval after submission of due diligence information to the National Ethics Committee. Additionally, NanoViricides is preparing NV-387 to combat measles outbreaks and bird flu, pointing to broad antiviral potential.

The measles outbreak in the USA underscores the urgency, with over 1,000 cases reported this year. The efficacy of NV-387 is further explored, given its promising results in lethal virus infection models. Financially, NanoViricides reported a cash balance of $2.73 million but lacks sufficient funding to continue its full operations through February 2026. The company plans to leverage equity markets and partnerships to secure additional resources needed for ongoing objectives and trials.